Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8926 to 8933 of 8933 results

  1. Learn more about the NICE and NHS England MedTech Pathway consultation

    Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode

  2. New option for adult leukaemia patients as we recommend treatment

    Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.

  3. New life-changing treatment option recommended for type of rare epilepsy

    This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.

  4. NICE's positive recommendations for lung cancer treatments

    Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're joined

  5. Avelumab not recommended as a maintenance treatment of urothelial cancer

    NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.

  6. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

  7. Patient safety and surgical innovation – why new isn't always better

    Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.

  8. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.